Ani pharmaceuticals announces the fda approval and launch of fluoxetine oral solution usp

Baudette, minn.--( business wire )--ani pharmaceuticals, inc. (“ani” or the “company”) (nasdaq: anip) today announced that the company received u.s. food and drug administration (fda) approval for the abbreviated new drug application (anda) for fluoxetine oral solution, usp 20 mg/5 ml.
ANIP Ratings Summary
ANIP Quant Ranking